ciprofloxacin has been researched along with Disease Exacerbation in 28 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 9.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 5.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "Ciprofloxacin accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture in Marfan mice, partially by suppressing lysyl oxidase expression and further compromising the inherited defect in aortic elastic fibers." | 4.12 | Ciprofloxacin accelerates aortic enlargement and promotes dissection and rupture in Marfan mice. ( Barrish, JP; Coselli, JS; LeMaire, SA; Luo, W; Shen, YH; Zhang, L; Zhang, NS; Zhang, Q, 2022) |
| " Twelve days later, she was diagnosed with posterior scleritis and treated with oral ciprofloxacin." | 3.73 | Posterior scleritis secondary to Pseudomonas aeruginosa keratitis. ( Dastjerdi, M; Fahim, K; Houghton, O; Mian, SI, 2005) |
| "In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes." | 3.71 | Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002) |
| "Upper respiratory tract infections (URTI) frequently cause exacerbations of chronic-obstructive pulmonary disease (COPD)." | 2.76 | Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial. ( Isbaniah, F; Setiawati, A; Totzke, U; Verbruggen, MA; Wiyono, WH; Yunus, F, 2011) |
| " The dosage regimens were-groups 1 and 2: 400 mg i." | 2.68 | Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. ( Blum, R; Heller, AH; Lettieri, J; Millikin, S; Shah, A; Sica, D, 1996) |
| "Necrotising otitis externa is a progressive infection of the external auditory canal which extends to affect the temporal bone and adjacent structures." | 2.66 | A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa. ( Baring, D; Bennett, A; Henderson, N; Hopkins, ME; MacSween, KF; Sutherland, R, 2020) |
| " Older literature supports an oral dosing regimen of 40 mg/kg/day divided every 12 hr, up to 2 g/day, and intravenous (IV) ciprofloxacin 30 mg/kg/day divided every 8 hr, maximum 1." | 2.49 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) |
| "Toxic epidermal necrolysis (TEN), or Lyell's syndrome, is a fulminant bullous dermatitis." | 1.32 | Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. ( Jongen-Lavrencic, M; Schneeberger, PM; van der Hoeven, JG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| LeMaire, SA | 1 |
| Zhang, L | 1 |
| Zhang, NS | 1 |
| Luo, W | 1 |
| Barrish, JP | 1 |
| Zhang, Q | 1 |
| Coselli, JS | 1 |
| Shen, YH | 1 |
| Salomon-Zimri, S | 1 |
| Pushett, A | 1 |
| Russek-Blum, N | 1 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 1 |
| Drory, VE | 1 |
| Hamid, K | 1 |
| Hamza, M | 1 |
| Naim, T | 1 |
| Shahid, M | 1 |
| Hsu, JL | 1 |
| Hopkins, ME | 1 |
| Bennett, A | 1 |
| Henderson, N | 1 |
| MacSween, KF | 1 |
| Baring, D | 1 |
| Sutherland, R | 1 |
| Sharma, A | 1 |
| De Rosa, M | 1 |
| Singla, N | 1 |
| Singh, G | 1 |
| Barnwal, RP | 1 |
| Pandey, A | 1 |
| Marí Cotino, JF | 1 |
| Suriano, MM | 1 |
| De La Cruz Aguiló, RI | 1 |
| Vila-Arteaga, J | 1 |
| Serisier, DJ | 1 |
| Bilton, D | 1 |
| De Soyza, A | 1 |
| Thompson, PJ | 1 |
| Kolbe, J | 1 |
| Greville, HW | 1 |
| Cipolla, D | 1 |
| Bruinenberg, P | 1 |
| Gonda, I | 1 |
| Cowart, DW | 1 |
| Moradi, BN | 1 |
| Arora, NS | 1 |
| López, E | 1 |
| Domenech, A | 1 |
| Ferrándiz, MJ | 1 |
| Frias, MJ | 1 |
| Ardanuy, C | 1 |
| Ramirez, M | 1 |
| García, E | 1 |
| Liñares, J | 1 |
| de la Campa, AG | 1 |
| Moghaddam, S | 1 |
| Connolly, D | 1 |
| Levine, AC | 1 |
| Shetty, PP | 1 |
| Henwood, PC | 1 |
| Sabeti, P | 1 |
| Katz, JT | 1 |
| Vaidya, A | 1 |
| Petru, E | 1 |
| Singer, CF | 1 |
| Polterauer, S | 1 |
| Galid, A | 1 |
| Schauer, C | 1 |
| Klocker, J | 1 |
| Seifert, M | 1 |
| Reinthaller, A | 1 |
| Benedicic, C | 1 |
| Hubalek, M | 1 |
| Hefler, L | 1 |
| Marth, C | 1 |
| Scholl-Firon, T | 1 |
| Bogner, G | 1 |
| Zeimet, AG | 1 |
| Fjaellegaard, K | 1 |
| Sin, MD | 1 |
| Browatzki, A | 1 |
| Ulrik, CS | 1 |
| Isbaniah, F | 1 |
| Wiyono, WH | 1 |
| Yunus, F | 1 |
| Setiawati, A | 1 |
| Totzke, U | 1 |
| Verbruggen, MA | 1 |
| Bock, K | 1 |
| Ovesen, T | 1 |
| Rianthavorn, P | 1 |
| Malamitsi, J | 1 |
| Papadopoulos, A | 1 |
| Vezyrgianni, A | 1 |
| Dalianis, K | 1 |
| Boutsikou, M | 1 |
| Giamarellou, H | 1 |
| Kuźniar, TJ | 1 |
| Kasibowska-Kuźniar, K | 1 |
| Grable, I | 1 |
| Mhaidli, HH | 1 |
| Der-Boghossian, AH | 1 |
| Haidar, RK | 1 |
| Stockmann, C | 1 |
| Sherwin, CM | 1 |
| Zobell, JT | 1 |
| Young, DC | 1 |
| Waters, CD | 1 |
| Spigarelli, MG | 1 |
| Ampofo, K | 1 |
| Bakker-Woudenberg, IA | 1 |
| ten Kate, MT | 1 |
| Guo, L | 1 |
| Working, P | 1 |
| Mouton, JW | 1 |
| Jongen-Lavrencic, M | 1 |
| Schneeberger, PM | 1 |
| van der Hoeven, JG | 1 |
| Fahim, K | 1 |
| Houghton, O | 1 |
| Dastjerdi, M | 1 |
| Mian, SI | 1 |
| Leus, B | 1 |
| Devreese, K | 1 |
| van den Bossche, J | 1 |
| Malfait, R | 1 |
| Elwood, ET | 1 |
| Sommerville, DN | 1 |
| Murray, JD | 1 |
| Contag, CH | 1 |
| Contag, PR | 1 |
| Mullins, JI | 1 |
| Spilman, SD | 1 |
| Stevenson, DK | 1 |
| Benaron, DA | 1 |
| Shah, A | 1 |
| Lettieri, J | 1 |
| Blum, R | 1 |
| Millikin, S | 1 |
| Sica, D | 1 |
| Heller, AH | 1 |
| Ryzhkova, VV | 1 |
| Pavlovich, NV | 1 |
| Makarovskaia, LN | 1 |
| Zurabian, VA | 1 |
| Bespalova, IA | 1 |
| Goncharov, EK | 1 |
| Bugaeva, OK | 1 |
| Malsova, NN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study[NCT03988816] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-12-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ciprofloxacin and Disease Exacerbation
| Article | Year |
|---|---|
A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cranial Nerve Diseases; Disease Progr | 2020 |
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Topics: Cause of Death; Ciprofloxacin; Contraindications; Delayed-Action Preparations; Disease Progression; | 2015 |
Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bronchiectasis; Ciprofloxacin; Colistin; Disease | 2017 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Dr | 2013 |
4 trials available for ciprofloxacin and Disease Exacerbation
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Delayed-Acti | 2013 |
Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ascorbic Acid; Ciprofloxacin; | 2011 |
Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Creatinine; Demography; Disease Progression; Dose | 1996 |
20 other studies available for ciprofloxacin and Disease Exacerbation
| Article | Year |
|---|---|
Ciprofloxacin accelerates aortic enlargement and promotes dissection and rupture in Marfan mice.
Topics: Animals; Anti-Bacterial Agents; Aorta; Aortic Aneurysm; Aortic Dissection; Aortic Rupture; Apoptosis | 2022 |
A Unique Case of Community Acquired Proteus mirabilis Meningitis.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Disease Progression; Female; Humans; I | 2022 |
Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.
Topics: Antitubercular Agents; Ciprofloxacin; Disease Progression; Drug Carriers; Drug Evaluation, Preclinic | 2021 |
Central toxic keratopathy: a clinical case series.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Astigmatism; Ciprofloxacin; C | 2013 |
A 50-year-old man with blistering skin lesions on both feet.
Topics: Blister; Ciprofloxacin; Disease Progression; Follow-Up Studies; Hawaii; Humans; Male; Middle Aged; N | 2013 |
Induction of prophages by fluoroquinolones in Streptococcus pneumoniae: implications for emergence of resistance in genetically-related clones.
Topics: Blotting, Southern; Chronic Disease; Ciprofloxacin; Disease Progression; Drug Resistance, Bacterial; | 2014 |
Photo-induced Stevens-Johnson syndrome.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dermatitis, Phototoxic; Disease Progression; Female; Humans; S | 2014 |
Interactive medical case. A Liberian health care worker with fever.
Topics: Anti-Bacterial Agents; Antibodies, Viral; Ciprofloxacin; Combined Modality Therapy; Diagnosis, Diffe | 2015 |
Optimised diagnosis and treatment of necrotizing external otitis is warranted.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; C-Reactive Protein; Ci | 2011 |
Progression and resolution of acute focal bacterial nephritis.
Topics: Acute Disease; Cefotaxime; Child, Preschool; Ciprofloxacin; Disease Progression; Drug Therapy, Combi | 2011 |
The value of successive Infecton scans in assessing the presence of chronic bone and joint infection and in predicting its evolution after treatment and after a prolonged follow-up.
Topics: Adult; Aged; Arthrography; Blood Sedimentation; Bone and Bones; Bone Diseases, Infectious; C-Reactiv | 2011 |
Parotid abscess in a patient with obstructive sleep apnea treated with continuous positive airway pressure therapy.
Topics: Abscess; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; | 2012 |
Propionibacterium acnes delayed infection following spinal surgery with instrumentation.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Delayed Diagnosis; Disease Progression; Fistula; Follow- | 2013 |
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression; | 2002 |
Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus.
Topics: Adult; Ciprofloxacin; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Humans; | 2003 |
Posterior scleritis secondary to Pseudomonas aeruginosa keratitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Corneal Ulcer; Disease Progression; Eye Enucleation; Eye Infec | 2005 |
Factor V inhibitor: case report.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Blood Coagulation Tests; Ciprofloxacin; Disease Progressi | 2006 |
Periorbital necrotizing fasciitis.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Breast Neoplasms; | 2007 |
Photonic detection of bacterial pathogens in living hosts.
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Disease Progression; Intestine, Larg | 1995 |
[Increased effectiveness of etiotropic therapy of experimental plague in albino mice at the stage of generalized infection].
Topics: Amikacin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Progression; Drug Evaluation, Precl | 1996 |